NasdaqGM:LPTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Leap Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LPTX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.0%

LPTX

0.7%

US Biotechs

1.8%

US Market


1 Year Return

39.7%

LPTX

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: LPTX exceeded the US Biotechs industry which returned 22% over the past year.

Return vs Market: LPTX exceeded the US Market which returned 3.7% over the past year.


Shareholder returns

LPTXIndustryMarket
7 Day-7.0%0.7%1.8%
30 Day-11.3%4.9%5.6%
90 Day-17.1%10.7%-7.4%
1 Year39.7%39.7%23.3%22.1%6.1%3.7%
3 Year-68.5%-68.5%36.3%31.7%28.3%19.8%
5 Yearn/a-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is Leap Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Leap Therapeutics undervalued compared to its fair value and its price relative to the market?

4.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LPTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LPTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LPTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LPTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LPTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LPTX is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Leap Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-2.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LPTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LPTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LPTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LPTX's revenue (40% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: LPTX's revenue (40% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LPTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Leap Therapeutics performed over the past 5 years?

-12.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LPTX is currently unprofitable.

Growing Profit Margin: LPTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LPTX is unprofitable, and losses have increased over the past 5 years at a rate of -12.2% per year.

Accelerating Growth: Unable to compare LPTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LPTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.3%).


Return on Equity

High ROE: LPTX has a negative Return on Equity (-175.51%), as it is currently unprofitable.


Next Steps

Financial Health

How is Leap Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: LPTX's short term assets ($26.0M) exceed its short term liabilities ($9.2M).

Long Term Liabilities: LPTX's short term assets ($26.0M) exceed its long term liabilities ($1.6M).


Debt to Equity History and Analysis

Debt Level: LPTX is debt free.

Reducing Debt: LPTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LPTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LPTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.9% each year


Next Steps

Dividend

What is Leap Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LPTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LPTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LPTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LPTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LPTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.08yrs

Average management tenure


CEO

Doug Onsi (50yo)

0.083

Tenure

US$816,959

Compensation

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since 2020. He serves as Managing Director of HealthCare Ventures LLC. He joined the HealthCare Ventures LLC in  ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD816.96K) is above average for companies of similar size in the US market ($USD596.47K).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Onsi
CFO, General Counsel0.083yrUS$816.96kno data
Augustine Lawlor
Chief Operating Officer4.33yrsUS$815.87kno data
Cynthia Sirard
Chief Medical Officer0.083yrno datano data
Mark O'Mahony
Chief Manufacturing Officer0.083yrno datano data
Walter Newman
Senior Research Fellowno datano datano data

0.08yrs

Average Tenure

50yo

Average Age

Experienced Management: LPTX's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Douglas Onsi
CFO, General Counsel0.083yrUS$816.96kno data
Christopher Mirabelli
Chairman4.33yrsUS$813.17kno data
James Cavanaugh
Independent Director4.33yrsUS$70.31kno data
Thomas Dietz
Lead Independent Directorno dataUS$100.54kno data
Nissim Mashiach
Independent Director3.33yrsUS$70.72kno data
Joseph Loscalzo
Independent Director4.33yrsUS$63.91kno data
William Li
Independent Director3.33yrsUS$63.91kno data
Carl Nathan
Member of Scientific Advisory Boardno datano datano data
Eric Winer
Member of Scientific Advisory Boardno datano datano data
David Tuveson
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Board: LPTX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56%.


Top Shareholders

Company Information

Leap Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Leap Therapeutics, Inc.
  • Ticker: LPTX
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$76.253m
  • Shares outstanding: 35.80m
  • Website: https://www.leaptx.com

Number of Employees


Location

  • Leap Therapeutics, Inc.
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge
  • Massachusetts
  • 2141
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LPTXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 2017
5MC1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2017

Biography

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company’s clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/24 05:10
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.